The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...